Our Take
Moderna's mRNA flu vaccine generates immune responses that persist longer and target a wider range of strains than inactivated shots, but the clinical win (26.6% relative risk reduction in Phase III) is modest and the persistent germinal center response was observed in only 5 of 13 people studied.
Why it matters
Flu vaccine strain mismatch drops efficacy from ~60% to 19% in bad years. A vaccine that works across divergent strains could reduce hospitalizations regardless of seasonal predictions, though this mRNA candidate is still awaiting FDA approval.
Do this week
Public health officials: monitor the FDA review timeline for mRNA-1010 and prepare messaging on germinal center durability claims, since policymakers will need to weigh the 26.6% Phase III improvement against the modest persistence rates in the immunology study.
Moderna's mRNA Flu Vaccine Produces Stronger, Broader Immune Responses
Moderna's investigational mRNA flu vaccine (mRNA-1010) generated a stronger and more durable immune response than the standard inactivated flu shot (Fluarix) in a clinical comparison study published today in Nature Immunology. Researchers followed 75 adults ages 20 to 50 across two flu seasons. Participants who received the mRNA vaccine produced more flu-specific antibodies and more flu-specific memory B cells than those who received the traditional shot.
The key difference lay in germinal center response. Germinal centers are immune structures where B cells improve their ability to recognize viruses and generate diverse versions of themselves. Among 13 participants receiving the mRNA vaccine, five developed persistent flu-specific germinal center responses in lymph nodes that lasted through the 26-week study period. None of the 15 participants who received the standard vaccine showed persistent germinal center responses.
Antibodies from mRNA vaccine recipients recognized and bound to a wider range of influenza strains across decades of viral evolution, particularly those associated with widespread disease. Antibodies from standard vaccine recipients bound to fewer divergent strains.
The mRNA vaccine also showed a clinical advantage in a separate Phase III trial. Among older adults, the mRNA vaccine reduced the risk of illness by 26.6% more than the standard flu vaccine (company-reported).
Flu Vaccines Fail When Virus Strains Shift
Today's flu vaccines are manufactured months before flu season based on WHO projections of which strains will circulate. When predictions miss, the mismatch is costly. Vaccine efficacy drops from roughly 60% in good years to 19% when strain predictions are wrong (per the published research). This mismatch affects roughly one billion people who receive flu shots annually.
A vaccine that arms the immune system against a broader portfolio of flu viruses could sidestep the annual guessing game. If an mRNA approach can reliably expand B cell diversity and persistence, it could reduce hospitalizations and deaths even when seasonal strains diverge from vaccine targets.
The FDA is currently reviewing mRNA-1010. If approved, it would be the first mRNA vaccine against influenza.
What Practitioners Should Watch
The germinal center finding is the anchor claim here, but the sample sizes matter. Persistent GC response was seen in five of 13 mRNA recipients. In immunology terms, this is real but not universal. The 26.6% relative risk reduction in Phase III is measurable but modest compared to the durability promise. Practitioners should track whether the FDA submission includes longer-term follow-up data on antibody persistence beyond 26 weeks and whether the germinal center response rate holds in larger cohorts.
The ability to bind divergent flu strains is the clinical payoff being tested. Independent validation from health systems post-approval will be essential to confirm whether this breadth translates to lower hospitalization rates in years when strain mismatch occurs.